JP2017533727A - 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 - Google Patents

固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 Download PDF

Info

Publication number
JP2017533727A
JP2017533727A JP2017538570A JP2017538570A JP2017533727A JP 2017533727 A JP2017533727 A JP 2017533727A JP 2017538570 A JP2017538570 A JP 2017538570A JP 2017538570 A JP2017538570 A JP 2017538570A JP 2017533727 A JP2017533727 A JP 2017533727A
Authority
JP
Japan
Prior art keywords
biomarker
subject
sample
level
solid tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017538570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533727A5 (enExample
Inventor
ハグナー パトリック
ハグナー パトリック
ガンディー アニタ
ガンディー アニタ
チョプラ ラジェシュ
チョプラ ラジェシュ
クリペル アンケ
クリペル アンケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2017533727A publication Critical patent/JP2017533727A/ja
Publication of JP2017533727A5 publication Critical patent/JP2017533727A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
JP2017538570A 2014-10-13 2014-12-05 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 Pending JP2017533727A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462063343P 2014-10-13 2014-10-13
US62/063,343 2014-10-13
US201462085127P 2014-11-26 2014-11-26
US62/085,127 2014-11-26
PCT/US2014/068802 WO2016060702A1 (en) 2014-10-13 2014-12-05 Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies

Publications (2)

Publication Number Publication Date
JP2017533727A true JP2017533727A (ja) 2017-11-16
JP2017533727A5 JP2017533727A5 (enExample) 2018-01-25

Family

ID=55747078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017538570A Pending JP2017533727A (ja) 2014-10-13 2014-12-05 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用

Country Status (4)

Country Link
US (1) US20170242014A1 (enExample)
EP (1) EP3207151A4 (enExample)
JP (1) JP2017533727A (enExample)
WO (1) WO2016060702A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525362A (ja) * 2018-05-23 2021-09-24 セルジーン コーポレイション 多発性骨髄腫を治療すること及び４−（４−（４−（（（２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−４−イル）オキシ）メチル）ベンジル）ピペラジン−１−イル）−３−フルオロベンゾニトリルのバイオマーカーの使用
JP2022526131A (ja) * 2019-03-22 2022-05-23 ユニヴァーシティー オブ ウルサン ファウンデイション フォー インダストリー コーオペレイション 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5388854B2 (ja) 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
LT3202461T (lt) 2010-02-11 2019-04-25 Celgene Corporation Arilmetoksiizoindolino dariniai ir juos apimančios kompozicijos bei jų panaudojimo būdai
SMT201800032T1 (it) 2011-03-11 2018-03-08 Celgene Corp Forme solide di 3-(5-ammino-2-metil-4-osso-4h-chinazolin-3-il)-piperidina-2,6-dione, e loro composizioni farmaceutiche e usi
US9682952B2 (en) 2012-09-04 2017-06-20 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US10338077B2 (en) 2015-06-02 2019-07-02 Celgene Corporation Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins
KR20180052747A (ko) 2015-09-25 2018-05-18 셀진 코포레이션 미만성 거대 b세포 림프종의 치료 방법 및 약물에 대한 반응성의 예측자로서 바이오마커의 용도
US10648983B2 (en) 2016-01-08 2020-05-12 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
WO2018010142A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
WO2023102193A1 (en) * 2021-12-02 2023-06-08 Ohio State Innovation Foundation Methods and compositions related to inflammatory gene panel
EP4533101A2 (en) * 2022-05-27 2025-04-09 Bristol-Myers Squibb Company Biomarkers for chronic fatigue syndrome and long covid and uses thereof
CN115078722A (zh) * 2022-06-08 2022-09-20 北京化工大学 一种筛选鉴定肝细胞癌的方法及其应用
CN115407068B (zh) * 2022-09-20 2024-07-12 华中科技大学同济医学院附属协和医院 Oma1蛋白作为胶质瘤标记物的应用及其试剂盒
CN119709998B (zh) * 2024-11-28 2025-10-10 北京大学深圳医院（北京大学深圳临床医学院） 检测circATP2B4的试剂在制备用于诊断口腔鳞状细胞癌的产品中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP2010504530A (ja) * 2006-09-19 2010-02-12 ノバルティス アーゲー Ｒａｆ阻害剤の標的調節、効果、診断、および／または予後診断のためのバイオマーカー
WO2012153187A2 (en) * 2011-05-06 2012-11-15 Xentech Markers for cancer prognosis and therapy and methods of use
WO2013106686A1 (en) * 2012-01-13 2013-07-18 Celgene Corporation Biomarkers for the treatment of hepatocellular carcinoma
WO2014004990A2 (en) * 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
JP2014514579A (ja) * 2011-04-29 2014-06-19 セルジーン コーポレイション セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084992A2 (en) * 2006-01-19 2007-07-26 The University Of Chicago Prognosis and therapy predictive markers and methods of use
WO2008005281A2 (en) * 2006-06-30 2008-01-10 Rosetta Inpharmatics Llc Genes associated with chemotherapy response and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP2010504530A (ja) * 2006-09-19 2010-02-12 ノバルティス アーゲー Ｒａｆ阻害剤の標的調節、効果、診断、および／または予後診断のためのバイオマーカー
JP2014514579A (ja) * 2011-04-29 2014-06-19 セルジーン コーポレイション セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法
WO2012153187A2 (en) * 2011-05-06 2012-11-15 Xentech Markers for cancer prognosis and therapy and methods of use
WO2013106686A1 (en) * 2012-01-13 2013-07-18 Celgene Corporation Biomarkers for the treatment of hepatocellular carcinoma
WO2014004990A2 (en) * 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525362A (ja) * 2018-05-23 2021-09-24 セルジーン コーポレイション 多発性骨髄腫を治療すること及び４−（４−（４−（（（２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−４−イル）オキシ）メチル）ベンジル）ピペラジン−１−イル）−３−フルオロベンゾニトリルのバイオマーカーの使用
JP7495886B2 (ja) 2018-05-23 2024-06-05 セルジーン コーポレイション 多発性骨髄腫を治療すること及び４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルのバイオマーカーの使用
JP2022526131A (ja) * 2019-03-22 2022-05-23 ユニヴァーシティー オブ ウルサン ファウンデイション フォー インダストリー コーオペレイション 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体
JP7300687B2 (ja) 2019-03-22 2023-06-30 ユニヴァーシティー オブ ウルサン ファウンデイション フォー インダストリー コーオペレイション 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体

Also Published As

Publication number Publication date
WO2016060702A1 (en) 2016-04-21
US20170242014A1 (en) 2017-08-24
EP3207151A4 (en) 2018-07-04
EP3207151A1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
JP2017533727A (ja) 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用
JP7142612B2 (ja) びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法
US20180231561A1 (en) Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
JP6880037B2 (ja) がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
RU2760686C2 (ru) Производные хинолина для лечения воспалительных заболеваний
JP6585737B2 (ja) セレブロン関連タンパク質の比を使用してがんの治療のための薬物の有効性を決定するための方法
US8901110B2 (en) Use of biomarkers in methods for the treatment of hepatocellular carcinoma
JP2011505808A (ja) 非ホジキンリンパ腫の治療の間における、免疫調節化合物に対する細胞の感受性を予測するためのバイオマーカー
US20180267043A1 (en) Use of biomarkers for predicting clinical sensitivity to cancer treatment
EP3331613A1 (en) Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
KR20180052747A (ko) 미만성 거대 b세포 림프종의 치료 방법 및 약물에 대한 반응성의 예측자로서 바이오마커의 용도
US20190187141A1 (en) Biomarkers for Detection and Treatment of Mast Cell Activity-Associated Disorders
JP2011505807A (ja) キナゾリノン化合物による治療をモニタリングするためのバイオマーカー

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171201

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20171201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181009

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190514